Author

David P. Hudesman 1

1 Inflammatory Bowel Disease Center a

ASSOCIATION BETWEEN DURATION OF LATEST FLARE BEFORE INDUCTION TREATMENT WITH TOFACITINIB AND EFFICACY OUTCOMES IN PATIENTS WITH ULCERATIVE COLITIS

Geert D’Haens, Alessandro Armuzzi, Chinyu Su, Xiang Guo, Irene Modesto, Rajiv Mundayat, David P. Hudesman, Michael Chiorean

Faecal calprotectin levels, C-reactive protein levels and partial Mayo score as early predictors of clinical and endoscopic outcomes in adult patients with moderately to severely active ulcerative colitis treated with tofacitinib in a Phase 2 study

Marla C. Dubinsky, David P. Hudesman, nicole kulisek, Leonardo Salese, Jerome Paulissen, Chinyu Su, Fernando Magro

PATIENT-REPORTED OUTCOME IMPROVEMENT WITH TOFACITINIB IN THE ULCERATIVE COLITIS OCTAVE CLINICAL PROGRAMME

Mahmoud Mosli, David P. Hudesman, Joana Torres, Leonardo Salese, John C. Woolcott, Rajiv Mundayat, Chinyu Su, Jessica Allegretti

PATIENT-REPORTED OUTCOME IMPROVEMENT WITH TOFACITINIB IN THE ULCERATIVE COLITIS OCTAVE CLINICAL PROGRAMME

David P. Hudesman

SERUM LIPID AND C-REACTIVE PROTEIN LEVELS BY TREATMENT RESPONSE FOLLOWING 8 WEEKS OF TOFACITINIB INDUCTION THERAPY IN PATIENTS WITH ULCERATIVE COLITIS

Christina Ha, Leonardo Salese, Chinyu Su, Krisztina B Gecse, John Woolcott, Rajiv Mundayat, David P. Hudesman, Jerome Paulissen, Walter Reinisch

Item 1 - 5 / 5
1